...
首页> 外文期刊>Journal of clinical laboratory analysis. >Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study
【24h】

Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study

机译:益生菌改善糖尿病肾病患者的血糖控制:随机临床研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective This research aimed to explore the effects of probiotic administration on glycemic control and renal function in patients with diabetic nephropathy (DN). Methods The 101 participants were randomly divided into two treatment groups and 76 patients were included in the final analysis. In 76 patients with diabetic nephropathy of type 2 diabetes, a randomized double‐blind and placebo‐controlled clinical trial was conducted to evaluate the administration of 3.2?×?10 9 ?CFU probiotic supplements per day ( Bifidobacterium bifidum , 1.2?×?10 9 ?CFU, Lactobacillus acidophilus 4.2?×?10 9 ?CFU, Streptococcus thermophilus 4.3?×?10 9 ?CFU) for 12?weeks on glycemic control of patients, including fasting blood glucose, 2?h postprandial blood glucose, glycosylated hemoglobin (HbA1c),?microalbuminuria/creatinine (mAlb/Cr) and estimated glomerular filtration rate (eGFR) levels. The placebo group daily received empty capsules filled with starch. Results After 12?weeks, the administration of probiotics demonstrated a significant reduction in fasting blood glucose (10.68?±?3.24?mmol/L before vs. 7.81?±?2.77?mmol/L after, p ?0.05), HbA1c (8.19?±?1.60% before vs. 7.32?±?1.20% after, p ?0.05) and mAlb/Cr (101.60?±?22.17?mg/g before vs. 67.53?±?20.11?mg/g after, p ?0.05), while only mAlb/Cr level was significantly lower in the probiotic group than in the placebo group after intervention (67.53?±?20.11?mg/g vs. 87.71?±?23.01, p ?0.05). Meanwhile, there was no significant reduction of 2?h postprandial blood glucose level (18.95?±?5.23?mmol/L vs. 17.35?±?6.28?mmol/L, p =?0.24) and eGFR (84.34?±?6.97?ml/min vs. 82.8?±?8.72?ml/min, p =?0.45) in patients before and after probiotic intake. In addition, the placebo group failed to show any significant change of these parameters. Conclusion This clinical study revealed probiotic administration could ameliorate glycemic control of patients with diabetic nephropathy, potentiating its therapeutic potential in clinical application.
机译:目的本研究旨在探讨益生菌给药对糖尿病肾病(DN)患者血糖控制和肾功能的影响。方法将101名参与者随机分为两种治疗组,76名患者均纳入最终分析。在76例糖尿病患者的糖尿病患者中,进行了随机双盲和安慰剂对照的临床试验,评价3.2×10 9?CFU益生菌补充剂(双歧杆菌Bifidum,1.2?×10 9?CFU,乳杆菌,嗜酸乳杆菌4.2?×10 9?CFU,链球菌,链球菌嗜热4.3?×10 9?CFU)12?患者血糖控制血糖,包括禁食血糖,2〜H后血糖,糖基化血红蛋白,糖基化血红蛋白(HBA1C),多稳脉尿/肌酐(MALB / CR)和估计的肾小球过滤速率(EGFR)水平。安慰剂集团每日收到填充淀粉的空胶囊。结果在12?周后,益生菌的给药在禁食血糖中表现出显着的减少(10.68?±3.24?mmol / L.之前,p&&?0.05以后,p&lt ;???0.05),HBA1C (8.19?±±1.60%,比率为7.32±1.20%,P& 0.05)和Malb / Cr(101.60?±22.17×20.17?mg / g在与67.53之前的情况(101.60?±22.17)?20.11?mg / g之后,P& 0.05),益生菌组中只有MALB / Cr水平显着低于安慰剂组(67.53?±20.11?mg / g与87.71Δ±23.01,P& ?0.05)。同时,2μm血糖水平没有显着减少(18.95?±5.23?mmol / L vs.17.35?±6.28?mmol / L,p =?0.24)和EGFR(84.34?±6.97在益生菌进气之前和之后患者中,Ml / min与82.8?±8.72?ml / min,p = 0.45)。此外,安慰剂组未能显示这些参数的任何重大变化。结论该临床研究揭示了益生菌给药可以改善糖尿病肾病患者的血糖控制,增强其治疗临床应用的治疗潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号